Amazentis S.A.

40 patents currently held · Updated Nov 14, 2026

4 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Aug 2030

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Apr 15, 2027
The maintenance fee for Compositions Comprising an Urolithin Compound (US 10,442,784) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
1 fee due May 26, 2027
The maintenance fee for Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders (US 10,485,782) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
2 fees due Jul 14 to 23, 2027 · next Jul 14
1 fee due Aug 20, 2027
The maintenance fee for Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders (US 11,903,922) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
3 fees due Sep 12 to 19, 2027 · next Sep 12
1 fee due Oct 30, 2027
The maintenance fee for Method for improving mitophagy in subjects (US 11,969,408) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,980,980	Compounds, compositions and methods for protecting brain health in neurodegenerative disorders In force Term ends Aug 28, 2030 · From the USPTO record	In force	Term ends Aug 28, 2030	From the USPTO record
US 8,933,217	Compounds, compositions, and methods for protecting brain health in neurodegenerative disorders In force Term ends Dec 27, 2030 · From the USPTO record	In force	Term ends Dec 27, 2030	From the USPTO record
US 12,310,943	Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders In force Term ends Dec 23, 2031 · Medium confidence	In force	Term ends Dec 23, 2031	Medium confidence
US 12,036,205	Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders In force Ends no later than Mar 18, 2032 · Medium confidence	In force	Ends no later than Mar 18, 2032	Medium confidence
US 9,872,850	Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders In force Ends no later than Apr 11, 2032 · Medium confidence	In force	Ends no later than Apr 11, 2032	Medium confidence
US 10,028,932	Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders In force Term ends Apr 11, 2032 · Medium confidence	In force	Term ends Apr 11, 2032	Medium confidence
US 10,485,782	Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders In force Term ends Nov 4, 2032 · High confidence	In force	Term ends Nov 4, 2032	High confidence
US 10,857,126	Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders In force Term ends Nov 4, 2032 · High confidence	In force	Term ends Nov 4, 2032	High confidence
US 11,903,922	Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders In force Term ends Nov 4, 2032 · High confidence	In force	Term ends Nov 4, 2032	High confidence
US 11,166,937	Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders In force Term ends Feb 21, 2033 · High confidence	In force	Term ends Feb 21, 2033	High confidence

10 of 40 patents shown.

Pro members see all 40.

Pro members: see all 40 patents

Also on record, not counted in the 40: 4 patents in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

16 pending · 4 abandoned · 2 no status recorded

List them